Published in Ann Intern Med on July 17, 2001
Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med (2010) 8.48
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med (2008) 3.71
Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest (2006) 3.41
Chronic kidney disease in children: the global perspective. Pediatr Nephrol (2007) 3.05
Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol (2010) 3.01
A simple algorithm to predict incident kidney disease. Arch Intern Med (2008) 2.36
Avosentan for overt diabetic nephropathy. J Am Soc Nephrol (2010) 2.32
Population based screening for chronic kidney disease: cost effectiveness study. BMJ (2010) 2.19
Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol (2009) 2.04
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2007) 2.01
A multi-marker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol (2010) 1.95
Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol (2009) 1.86
Magnitude of underascertainment of impaired kidney function in older adults with normal serum creatinine. J Am Geriatr Soc (2007) 1.85
Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant (2012) 1.83
Automated clinical reminders for primary care providers in the care of CKD: a small cluster-randomized controlled trial. Am J Kidney Dis (2011) 1.66
A cluster randomized trial of an enhanced eGFR prompt in chronic kidney disease. Clin J Am Soc Nephrol (2012) 1.57
The epidemic of pediatric chronic kidney disease: the danger of skepticism. J Nephropathol (2012) 1.55
The effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a pooled analysis of individual-patient data from 11 randomized, controlled trials. Ann Intern Med (2001) 1.44
Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol (2012) 1.42
A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int (2011) 1.37
The costs and benefits of automatic estimated glomerular filtration rate reporting. Clin J Am Soc Nephrol (2009) 1.31
Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol (2009) 1.29
Online clinical pathway for managing adults with chronic kidney disease. Can Pharm J (Ott) (2015) 1.25
Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol (2012) 1.21
One risk assessment tool for cardiovascular disease, type 2 diabetes, and chronic kidney disease. Diabetes Care (2012) 1.21
High prevalence of chronic kidney disease in Iran: a large population-based study. BMC Public Health (2009) 1.21
Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J Am Soc Nephrol (2013) 1.17
Remission of renal disease: recounting the challenge, acquiring the goal. J Clin Invest (2002) 1.14
Cardiovascular risk factors in patients with chronic kidney disease. Nat Rev Cardiol (2009) 1.09
Public health consequences of chronic kidney disease. Clin Pharmacol Ther (2009) 1.07
Implementation of a CKD checklist for primary care providers. Clin J Am Soc Nephrol (2014) 1.07
Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol (2014) 1.02
Glomerular filtration rate: screening cannot be recommended on the basis of current knowledge. BMJ (2006) 1.02
Chapter 10: Immunoglobulin A nephropathy. Kidney Int Suppl (2011) (2012) 1.01
Enalapril in children with Alport syndrome. Pediatr Nephrol (2004) 1.01
Kidney function can improve in patients with hypertensive CKD. J Am Soc Nephrol (2012) 0.99
Therapeutic strategies to slow chronic kidney disease progression. Pediatr Nephrol (2008) 0.99
Hypertension in children with chronic kidney disease: pathophysiology and management. Pediatr Nephrol (2007) 0.97
Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. Br J Clin Pharmacol (2013) 0.96
Diabetic nephropathy: a disorder of oxygen metabolism? Nat Rev Nephrol (2009) 0.94
A risk score for chronic kidney disease in the general population. Am J Med (2012) 0.93
Nurse practitioner care improves renal outcome in patients with CKD. J Am Soc Nephrol (2013) 0.92
Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis (2014) 0.92
NGAL-Siderocalin in kidney disease. Biochim Biophys Acta (2012) 0.92
Challenges of conducting a trial of uric-acid-lowering therapy in CKD. Nat Rev Nephrol (2011) 0.90
Prevalence and Correlates of CKD in Hispanics/Latinos in the United States. Clin J Am Soc Nephrol (2015) 0.89
Early pancreas graft failure is associated with inferior late clinical outcomes after simultaneous kidney-pancreas transplantation. Transplantation (2011) 0.89
Enalapril dosage in steroid-resistant nephrotic syndrome. Pediatr Nephrol (2003) 0.89
Olmesartan is More Effective Than Other Angiotensin Receptor Antagonists in Reducing Proteinuria in Patients With Chronic Kidney Disease Other Than Diabetic Nephropathy. Curr Ther Res Clin Exp (2013) 0.88
Hemodynamic correlates of proteinuria in chronic kidney disease. Clin J Am Soc Nephrol (2011) 0.88
Slowing progression of chronic kidney disease. Kidney Int Suppl (2011) (2013) 0.88
Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome. Pediatr Nephrol (2004) 0.87
Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome. Clin Exp Nephrol (2010) 0.87
Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vasc Health Risk Manag (2010) 0.87
Screening for chronic kidney disease: preventing harm or harming the healthy? PLoS Med (2012) 0.86
Prevalence, determinants, and management of chronic kidney disease in Karachi, Pakistan - a community based cross-sectional study. BMC Nephrol (2014) 0.86
Limitations and future treatment options in type 2 diabetes with renal impairment. Diabetes Care (2011) 0.86
Hypertension in Cardiovascular and Kidney Disease. Cardiorenal Med (2011) 0.85
Primary care physicians' familiarity, beliefs, and perceived barriers to practice guidelines in non-diabetic CKD: a survey study. BMC Nephrol (2014) 0.85
Direct Renin inhibitor: aliskiren in chronic kidney disease. Nephrourol Mon (2012) 0.84
Peripheral artery disease and chronic kidney disease: clinical synergy to improve outcomes. Adv Chronic Kidney Dis (2014) 0.84
Usefulness of RAS inhibition depends on baseline albuminuria. Nat Rev Nephrol (2010) 0.84
Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy?--A systematic review. Curr Control Trials Cardiovasc Med (2005) 0.84
Obstructive renal injury: from fluid mechanics to molecular cell biology. Open Access J Urol (2010) 0.84
Blood Pressure-Related Outcomes in a Diabetic Population. Hypertension (2016) 0.83
A simple model for predicting incidence of chronic kidney disease in HIV-infected patients. Clin Exp Nephrol (2011) 0.83
Rational use of antihypertensive medications in children. Pediatr Nephrol (2013) 0.82
Educational paper: Progression in chronic kidney disease and prevention strategies. Eur J Pediatr (2012) 0.82
Community pharmacist targeted screening for chronic kidney disease. Can Pharm J (Ott) (2016) 0.81
Using digital media to promote kidney disease education. Adv Chronic Kidney Dis (2013) 0.81
Association of the estimated 24-h urinary sodium excretion with albuminuria in adult koreans: the 2011 Korea National Health and Nutrition Examination Survey. PLoS One (2014) 0.81
Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. Clin J Am Soc Nephrol (2013) 0.81
Clinical outcomes in patients with chronic kidney disease: a 5-year retrospective cohort study at a University Hospital in Japan. Clin Exp Nephrol (2011) 0.80
Renal histomorphology in dogs with pyometra and control dogs, and long term clinical outcome with respect to signs of kidney disease. Acta Vet Scand (2007) 0.80
2013 Korean Society of Hypertension guidelines for the management of hypertension: part III-hypertension in special situations. Clin Hypertens (2015) 0.79
General practitioners' knowledge and approach to chronic kidney disease in Karachi, Pakistan. Indian J Nephrol (2013) 0.79
Doubling of serum creatinine: is it appropriate as the endpoint for CKD? Proposal of a new surrogate endpoint based on the reciprocal of serum creatinine. Clin Exp Nephrol (2010) 0.79
Cardiorenal connection in chronic kidney disease. Clin Exp Nephrol (2011) 0.79
Toward a more collaborative federal response to chronic kidney disease. Adv Chronic Kidney Dis (2010) 0.79
Health Education and General Practitioner Training in Hypertension Management: Long-Term Effects on Kidney Function. Clin J Am Soc Nephrol (2016) 0.78
Antihypertensive medication use and change in kidney function in elderly adults: a marginal structural model analysis. Int J Biostat (2011) 0.78
Manidipine-delapril combination in the management of hypertension. Vasc Health Risk Manag (2007) 0.78
Chapter 3: Blood pressure management in CKD ND patients without diabetes mellitus. Kidney Int Suppl (2011) (2012) 0.78
Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading. Clin Exp Nephrol (2013) 0.77
Slowing the progression of chronic renal insufficiency. CMAJ (2002) 0.77
Prevalence of microalbuminuria and diagnostic value of dipstick proteinuria in outpatients from HIV clinics in Bukavu, the Democratic Republic of Congo. BMC Nephrol (2014) 0.77
Is nocturnal blood pressure reduction the secret to reducing the rate of progression of hypertensive chronic kidney disease? Curr Hypertens Rep (2011) 0.77
Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol (2016) 0.77
Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy. Pediatr Nephrol (2011) 0.76
Association between Salt Intake and Albuminuria in Normotensive and Hypertensive Individuals. Int J Hypertens (2013) 0.76
Social Determinants of Racial Disparities in CKD. J Am Soc Nephrol (2016) 0.76
The effects of angiotensin-converting enzyme inhibitors on peritoneal protein loss and solute transport in peritoneal dialysis patients. Clinics (Sao Paulo) (2012) 0.76
Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease. Kidney Int (2015) 0.76
Corticosteroid Treatment Influences TA-Proteinuria and Renal Survival in IgA Nephropathy. PLoS One (2016) 0.75
Metabolic status and personality affect the prognosis of patients with continuous ambulatory peritoneal dialysis. Int J Clin Exp Med (2015) 0.75
Clinical utility of valsartan in the treatment of hypertension in children and adolescents. Patient Prefer Adherence (2011) 0.75
Renal failure (chronic). BMJ Clin Evid (2011) 0.75
Paediatrics: Long-term effects of Wilms tumour therapy on renal function. Nat Rev Urol (2015) 0.75
Conservative Management of Chronic Renal Failure. Med J Armed Forces India (2011) 0.75
The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease. Rambam Maimonides Med J (2015) 0.75
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA (1992) 22.27
Quantitative synthesis in systematic reviews. Ann Intern Med (1997) 11.72
The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med (1994) 11.65
Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses. Stat Med (2000) 11.03
Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem (1992) 8.84
Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA (2001) 8.15
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med (2013) 7.51
Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med (2001) 6.67
Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med (1998) 6.18
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med (1998) 6.17
Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA (2001) 5.96
Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med (1994) 5.72
Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med (1996) 5.46
The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med (1995) 5.21
Transmission of hepatitis C virus by organ transplantation. N Engl J Med (1991) 5.17
Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol (1981) 4.75
Summing up evidence: one answer is not always enough. Lancet (1998) 4.66
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet (1999) 4.38
Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med (1996) 4.18
Large trials vs meta-analysis of smaller trials: how do their results compare? JAMA (1996) 3.88
Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet (1999) 3.54
Health services: an Italian market. Lancet (1996) 3.43
Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med (1995) 3.41
The relationship between peritubular capillary protein concentration and fluid reabsorption by the renal proximal tubule. J Clin Invest (1969) 3.39
Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis (2000) 3.37
The comparative effects of postoperative analgesic therapies on pulmonary outcome: cumulative meta-analyses of randomized, controlled trials. Anesth Analg (1998) 3.32
Validation of comorbid conditions on the end-stage renal disease medical evidence report: the CHOICE study. Choices for Healthy Outcomes in Caring for ESRD. J Am Soc Nephrol (2000) 3.27
Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet (1993) 3.24
Progression, remission, regression of chronic renal diseases. Lancet (2001) 3.17
Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity? Lancet (1978) 3.15
The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med (1996) 3.15
Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness. Ann Intern Med (1995) 3.14
Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol (2001) 3.14
The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med (1982) 3.13
Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest (1985) 2.99
Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest (1986) 2.96
Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest (1986) 2.91
Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation (2000) 2.90
Modulating the profit motive to meet needs of the less-developed world. Lancet (2001) 2.86
A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int (2006) 2.85
Decision analysis: a progress report. Ann Intern Med (1987) 2.82
Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med (1992) 2.78
Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med (1997) 2.78
Issues in comparisons between meta-analyses and large trials. JAMA (1998) 2.77
Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol (1995) 2.74
Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med (2000) 2.74
Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol (1995) 2.73
Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int (2000) 2.72
X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol (2000) 2.71
Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med (1993) 2.70
Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med (2001) 2.69
Nephron adaptation to renal injury or ablation. Am J Physiol (1985) 2.65
Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med (1994) 2.62
Molecular basis of proteinuria of glomerular origin. N Engl J Med (1978) 2.61
The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol (2001) 2.56
Dynamics of glomerular ultrafiltration in the rat. IV. Determination of the ultrafiltration coefficient. J Clin Invest (1973) 2.55
Patient controlled opioid analgesia versus conventional opioid analgesia for postoperative pain. Cochrane Database Syst Rev (2006) 2.52
Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. Ann Intern Med (1997) 2.52
Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med (2001) 2.48
Strategies for making more organs available for transplantation. N Engl J Med (2000) 2.48
Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA (1998) 2.46
Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int (2001) 2.43
Long-term outcomes in nondiabetic chronic kidney disease. Kidney Int (2008) 2.41
Any casualties in the clash of randomised and observational evidence? BMJ (2001) 2.37
Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int (1981) 2.36
Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia (2010) 2.35
Intralaboratory reliability of serologic and urine testing for Lyme disease. Am J Med (2001) 2.34
A model of glomerular ultrafiltration in the rat. Am J Physiol (1972) 2.32
Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ (1996) 2.29
An evaluation of technologies for identifying acute cardiac ischemia in the emergency department: a report from a National Heart Attack Alert Program Working Group. Ann Emerg Med (1997) 2.27
Treatment of Lyme arthritis. Arthritis Rheum (1994) 2.27
The dynamics of glomerular ultrafiltration in the rat. J Clin Invest (1971) 2.27
The relationship between glomerular filtration rate and sodium reabsorption by the proximal tubule of the rat nephron. J Clin Invest (1968) 2.27
Long-term non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database Syst Rev (2005) 2.26
Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med (1984) 2.26
CREB-Binding protein acetylates hematopoietic transcription factor GATA-1 at functionally important sites. Mol Cell Biol (1999) 2.26
Dynamics of glomerular ultrafiltration in the rat. II. Plasma-flow dependence of GFR. Am J Physiol (1972) 2.24
Factor H family proteins: on complement, microbes and human diseases. Biochem Soc Trans (2002) 2.23
Inhibition of TGF-beta expression: a novel role for thiazolidinediones to implement renoprotection in diabetes. Kidney Int (2007) 2.19
Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int (2006) 2.18
Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev (2005) 2.17
Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med (1987) 2.16
Prognosis of patients with nonmalignant chronic intestinal failure receiving long-term home parenteral nutrition. Gastroenterology (1995) 2.16
The first clinical and epidemiological programme on renal disease in Bolivia: a model for prevention and early diagnosis of renal diseases in the developing countries. Nephrol Dial Transplant (1998) 2.16
Primary structure and functional expression of a cDNA encoding the thiazide-sensitive, electroneutral sodium-chloride cotransporter. Proc Natl Acad Sci U S A (1993) 2.15
Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int (1998) 2.14